Tenax Therapeutics Inc
NASDAQ:TENX

Watchlist Manager
Tenax Therapeutics Inc Logo
Tenax Therapeutics Inc
NASDAQ:TENX
Watchlist
Price: 16.05 USD -2.25% Market Closed
Market Cap: 100.2m USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Tenax Therapeutics Inc
NASDAQ:TENX
97m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
182.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
158.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Tenax Therapeutics Inc
Glance View

Market Cap
100.2m USD
Industry
Biotechnology

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company is headquartered in Morrisville, North Carolina and currently employs 8 full-time employees. The firm's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The firm's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for the treatment of pulmonary arterial hypertension (PAH), which is a fatal orphan disease. The firm has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

TENX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top